Loading
Raludotatug deruxtecan is a CDH6 ADC in phase 3 for platinum-resistant ovarian cancer.
Raludotatug deruxtecan is an anti-CDH6 IgG1 antibody linked through a cleavable GGFG linker to DXd, a topoisomerase I inhibitor that traps the enzyme on DNA and collapses replication forks; the payload crosses membranes, giving a bystander effect. CDH6 is a cadherin overexpressed in ovarian and renal cell carcinoma with little normal-tissue expression. Developed by Daiichi Sankyo with Merck, it produced an objective response rate around 46 percent in phase 1 in heavily pretreated ovarian cancer, and the REJOICE-Ovarian01 phase 2/3 trial is comparing it with chemotherapy in platinum-resistant disease at 5.6 mg/kg every 3 weeks. Nausea, fatigue, neutropenia and anaemia are the main toxicities, with interstitial lung disease monitored as for other DXd conjugates. Whether the response rate holds in a randomised trial is the open question for platinum-resistant ovarian cancer.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Anti-CDH6 IgG1 with DXd. Connects to CDH6.
1.Antibody binds CDH6 on the tumour cell surface
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Source: clinicaltrials.gov/study/NCT06161025. Doses are for orientation; the current label governs.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2023-10-20 | Daiichi Sankyo to Merck & Co. (MSD) Patritumab deruxtecan (HER3), ifinatamab deruxtecan (B7-H3) and raludotatug deruxtecan (CDH6) | Co-development | $4.0bn (plus $1.5bn in continuation payments over 24 months) | up to $22bn | source |
Phase 2/3 for the CDH6 ADC. Timing is a registry-based estimate. Source
Compare all products across the US, EU, UK, Japan, China and Australia →
Merck co-development of R-DXd under the Daiichi Sankyo alliance source
| Adverse event |
|---|
| Nausea |
| Fatigue |
| Neutropenia |
| Anaemia |
Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
| Country | Reimbursement | List price | Assistance |
|---|---|---|---|
| United States | Investigational (REJOICE-Ovarian01) | not disclosed | - |
List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Raludotatug deruxtecan" OR ABSTRACT:"Raludotatug deruxtecan" OR TITLE:"R-DXd" OR ABSTRACT:"R-DXd" OR TITLE:"DS-6000" OR ABSTRACT:"DS-6000") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Raludotatug deruxtecan, not a curated reading list.
Shares A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01), Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads.
Shares Tetrapeptide GGFG (maleimide-GGFG-aminomethyl), DXd, Topoisomerase-I inhibitor payloads, Daiichi Sankyo.
Shares Platinum-resistant ovarian cancer, Antibody-drug conjugate (ADC), Ovarian cancer.
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Daiichi Sankyo, Merck & Co. (MSD), Antibody-drug conjugate (ADC).